Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
BörsenkürzelSEER
Name des UnternehmensSeer Inc
IPO-datumDec 04, 2020
CEODr. Omid C. Farokhzad, M.D.
Anzahl der mitarbeiter134
WertpapierartOrdinary Share
GeschäftsjahresendeDec 04
Addresse3800 Bridge Parkway, Suite 102
StadtREDWOOD CITY
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94065
Telefon16504530000
Websitehttps://seer.bio/
BörsenkürzelSEER
IPO-datumDec 04, 2020
CEODr. Omid C. Farokhzad, M.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten